Compare FSK & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | NAMS |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2008 | N/A |
| Metric | FSK | NAMS |
|---|---|---|
| Price | $10.29 | $30.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $14.63 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 4.6M | 809.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $25.64 |
| Revenue Next Year | N/A | $530.85 |
| P/E Ratio | $261.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $14.06 |
| 52 Week High | $22.68 | $42.00 |
| Indicator | FSK | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 22.37 | 37.63 |
| Support Level | $10.28 | $23.48 |
| Resistance Level | $16.05 | $37.43 |
| Average True Range (ATR) | 0.47 | 1.75 |
| MACD | -0.09 | -0.37 |
| Stochastic Oscillator | 4.05 | 12.69 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.